PCRX vs COLL

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 23, 2026

PCRX

58.6
AI Score
VS
PCRX Wins

COLL

56.2
AI Score

Investment Advisor Scores

PCRX

59score
Recommendation
HOLD

COLL

56score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric PCRX COLL Winner
Revenue 393.40M 369.77M COLL
Net Income -555,000 7.57M PCRX
Net Margin -0.1% 2.0% PCRX
Operating Income 34.59M 11.17M COLL
ROE -0.2% 1.1% PCRX
ROA -0.0% 0.6% PCRX
Total Assets 2.14B 1.24B COLL
Cash 129.47M 205.88M PCRX
Current Ratio 1.03 5.04 PCRX
Free Cash Flow 127.67M 79.08M COLL

Relative Price Performance (Last 90 Days)

PCRX 1M: -4.9% · 3M: +5.1% COLL 1M: -23.8% · 3M: -21.2%

Current Technical Phase

PCRX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 49.5 · Price: $24.67

COLL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.9%), weak momentum, RSI 32

RSI (14): 32.0 · Price: $27.11

Fundamentals Snapshot

Metric PCRX COLL
Market Cap
Forward P/E 6.9 4.0
Trailing P/E 67.7 21.7
Revenue (TTM)
Revenue Growth 0.1% 0.1%
Gross Margin 0.8% 0.9%
Operating Margin 0.1% 0.1%
EPS 0.36 1.27
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.